Literature DB >> 22728518

Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma.

Seiji Mabuchi1, Mika Okazawa, Koji Matsuo, Mahiru Kawano, Osamu Suzuki, Takashi Miyatake, Takayuki Enomoto, Shoji Kamiura, Kazuhiko Ogawa, Tadashi Kimura.   

Abstract

OBJECTIVES: To evaluate the significance of adenocarcinoma (AC) compared with squamous cell carcinoma (SCC) with regard to the survival of surgically-treated early stage cervical cancer patients.
METHODS: We retrospectively reviewed the medical records of 520 patients with FIGO stage IA2-IIB cervical cancer who were treated with radical hysterectomy with or without adjuvant radiotherapy between January 1998 and December 2008. The patients were classified according to (i) pathological risk factors (low-, intermediate-, or high-risk group) and (ii) adjuvant radiotherapy (concurrent chemoradiotherapy [CCRT group] or radiotherapy alone [RT group]). Survival outcomes were examined by Kaplan-Meier method and compared with Log-rank test. Multivariate analysis for disease-specific survival (DSS) was performed using Cox proportional hazards regression model to investigate the prognostic significance of histological subtype.
RESULTS: AC histology was associated with significantly decreased DSS compared with SCC histology in the intermediate- and high-risk groups (hazard ratio: 3.06 and 2.88, respectively, both P<0.05) while there was no survival difference in the low-risk group (P=0.1). Among patients who received any types of adjuvant radiotherapy, DSS of AC histology patients were significantly poorer than SCC histology. Multivariate analysis demonstrated AC histology to be an independent predictor of decreased DSS in both CCRT and RT groups. Moreover, pelvic nodal metastasis significantly predicted the poor survival of patients with AC histology who received CCRT in multivariate analysis
CONCLUSIONS: Adenocarcinoma is an independent prognostic indicator of poor survival in early stage cervical cancer patients with intermediate- and high-risk factors, regardless of the type of adjuvant radiotherapy after radical hysterectomy.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22728518     DOI: 10.1016/j.ygyno.2012.06.021

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  30 in total

1.  Neoadjuvant chemotherapy followed by radical surgery as an alternative treatment to concurrent chemoradiotherapy for young premenopausal patients with FIGO stage IIB squamous cervical carcinoma.

Authors:  ShanShan Yang; Ying Gao; Jing Sun; Bairong Xia; TianBo Liu; HongXia Zhang; Qi Li; Min Xiao; YunYan Zhang
Journal:  Tumour Biol       Date:  2015-01-21

2.  Combination of external beam radiotherapy and Californium (Cf)-252 neutron intracavity brachytherapy is more effective in control of cervical squamous cell carcinoma than that of cervical adenocarcinoma.

Authors:  Yanli Xiong; Jia Liu; Shu Chen; Qian Zhou; Wenjing Xu; Chen Tang; Yonghong Chen; Mei Yang; Xin Lei
Journal:  Med Oncol       Date:  2015-08-14       Impact factor: 3.064

3.  Increased expression of iASPP correlates with poor prognosis in FIGO IA2-IIA cervical adenocarcinoma following a curative resection.

Authors:  Fanming Kong; Xiaofeng Shi; Huzi Li; Pu Li; Jianchun Yu; XiaoJiang Li; Jun Chen; Yiyu Sun; Yingjie Jia
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

4.  [S3 guidelines on diagnostics and treatment of cervical cancer: Demands on pathology].

Authors:  L-C Horn; M W Beckmann; M Follmann; M C Koch; P Mallmann; S Marnitz; D Schmidt
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

5.  A comparison of the prognosis between adenocarcinoma and squamous cell carcinoma in stage IB-IIA cervical cancer.

Authors:  Xiuzhen Xie; Kun Song; Baoxia Cui; Jie Jiang; Xingsheng Yang; Beihua Kong
Journal:  Int J Clin Oncol       Date:  2018-01-03       Impact factor: 3.402

6.  Comparison of clinical outcomes of squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the uterine cervix after definitive radiotherapy: a population-based analysis.

Authors:  Juan Zhou; San-Gang Wu; Jia-Yuan Sun; Feng-Yan Li; Huan-Xin Lin; Qiong-Hua Chen; Zhen-Yu He
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-19       Impact factor: 4.553

7.  MRI outcome evaluation in patients with IB2 and IIA2 squamous cervical cancer stages: preliminary results.

Authors:  Qingling Song; Huiting Pang; Rui Tong; Yanmei Zhu; Yahong Luo; Tao Yu; Fan Liu; Yue Dong
Journal:  Insights Imaging       Date:  2022-09-16

8.  Low-dose SN-38 with paclitaxel induces lethality in human uterine cervical adenocarcinoma cells by increasing caspase activity.

Authors:  Mizue Teramoto; Takahiro Suzuki; Seiro Satohisa; Yushi Akashi; Motoki Matsuura; Miwa Suzuki; Ryoichi Tanaka; Tsuyoshi Saito
Journal:  Med Mol Morphol       Date:  2013-03-16       Impact factor: 2.309

9.  Prognostic evaluation of postoperative adjuvant therapy for operable cervical cancer: 10 years' experience of National Cancer Center in China.

Authors:  Tong Shu; Dan Zhao; Bin Li; Yating Wang; Shuanghuan Liu; Pingping Li; Jing Zuo; Ping Bai; Rong Zhang; Lingying Wu
Journal:  Chin J Cancer Res       Date:  2017-12       Impact factor: 5.087

10.  Adjuvant hysterectomy following primary chemoradiation for stage IB2 and IIA2 cervical cancer: a retrospective comparison of complications for open versus minimally invasive surgery.

Authors:  Heather Miller; Koji Matsuo; Lynda D Roman; Annie A Yessaian; Huyen Q Pham; Marianne Hom; Antonio Castaneda; Anthony Pham; Omar Ragab; Laila Muderspach; Marcia Ciccone; Laurie L Brunette
Journal:  Radiat Oncol       Date:  2021-06-29       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.